Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.701
AS - Asia 13.842
EU - Europa 8.693
SA - Sud America 2.131
Continente sconosciuto - Info sul continente non disponibili 1.116
AF - Africa 325
OC - Oceania 27
Totale 44.835
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.295
SG - Singapore 4.670
IT - Italia 3.113
VN - Vietnam 2.697
CN - Cina 2.298
HK - Hong Kong 1.982
BR - Brasile 1.612
RU - Federazione Russa 1.486
CA - Canada 1.139
IE - Irlanda 932
DE - Germania 791
SE - Svezia 586
BD - Bangladesh 482
FR - Francia 407
GB - Regno Unito 399
IN - India 344
ID - Indonesia 252
UA - Ucraina 217
AR - Argentina 197
FI - Finlandia 181
KR - Corea 176
TR - Turchia 142
ZA - Sudafrica 129
MX - Messico 125
NL - Olanda 122
JP - Giappone 115
IQ - Iraq 109
PK - Pakistan 105
AT - Austria 80
PL - Polonia 76
EC - Ecuador 75
CO - Colombia 71
ES - Italia 71
SA - Arabia Saudita 69
UZ - Uzbekistan 65
PH - Filippine 55
CH - Svizzera 45
MA - Marocco 45
VE - Venezuela 37
PY - Paraguay 36
CL - Cile 35
JM - Giamaica 32
PE - Perù 31
BE - Belgio 30
MY - Malesia 30
DK - Danimarca 28
EG - Egitto 28
AE - Emirati Arabi Uniti 27
KE - Kenya 27
JO - Giordania 24
TN - Tunisia 24
TW - Taiwan 23
AU - Australia 22
TH - Thailandia 21
UY - Uruguay 20
CZ - Repubblica Ceca 18
HN - Honduras 18
DZ - Algeria 17
PT - Portogallo 17
NP - Nepal 16
IL - Israele 14
LT - Lituania 14
AZ - Azerbaigian 13
BO - Bolivia 13
DO - Repubblica Dominicana 13
NI - Nicaragua 13
BB - Barbados 12
CR - Costa Rica 12
RO - Romania 12
ET - Etiopia 11
KZ - Kazakistan 11
PS - Palestinian Territory 11
AL - Albania 10
KG - Kirghizistan 10
OM - Oman 10
SN - Senegal 10
GR - Grecia 9
GT - Guatemala 9
IR - Iran 8
LB - Libano 8
TT - Trinidad e Tobago 8
BY - Bielorussia 7
MN - Mongolia 7
NG - Nigeria 7
RS - Serbia 7
BG - Bulgaria 6
BH - Bahrain 6
GE - Georgia 6
HU - Ungheria 6
LV - Lettonia 5
NZ - Nuova Zelanda 5
PA - Panama 5
PR - Porto Rico 5
QA - Qatar 5
SV - El Salvador 5
XK - ???statistics.table.value.countryCode.XK??? 5
CI - Costa d'Avorio 4
HR - Croazia 4
KH - Cambogia 4
LY - Libia 4
Totale 43.650
Salva come PNG Salva come JPEG
Città #
Singapore 2.686
Hong Kong 1.952
Ashburn 1.598
Ann Arbor 1.515
Fairfield 1.223
San Jose 1.191
Dublin 912
Toronto 910
Milan 873
Ho Chi Minh City 837
Hanoi 664
Wilmington 612
New York 524
Seattle 521
Woodbridge 518
Frankfurt am Main 509
Houston 483
Chandler 474
Dallas 447
Santa Clara 443
Council Bluffs 421
Chicago 391
Cambridge 390
Princeton 370
Los Angeles 331
The Dalles 320
Beijing 312
Hefei 275
Dearborn 272
Rome 267
Lauterbourg 214
Jakarta 182
Moscow 169
Seoul 164
Altamura 161
Nanjing 158
Jacksonville 157
São Paulo 157
Buffalo 150
Lawrence 139
Columbus 136
Boardman 127
Helsinki 120
Haiphong 103
Shanghai 103
Da Nang 95
San Diego 89
Munich 87
London 83
Ottawa 82
Orem 79
Tokyo 67
Andover 66
Johannesburg 66
Guangzhou 64
Nuremberg 63
Phoenix 62
Tashkent 59
Rio de Janeiro 57
Warsaw 57
Montreal 55
Turin 54
Naples 51
Atlanta 50
Denver 48
Shenyang 47
Dong Ket 46
Hải Dương 46
Mexico City 45
Vienna 45
Brooklyn 44
Biên Hòa 43
Bologna 42
Figino 41
Hebei 41
Monza 41
Ha Long 40
Can Tho 39
Chennai 39
Stockholm 39
Lappeenranta 37
Baghdad 36
Brasília 36
Nanchang 36
Salt Lake City 36
Dhaka 35
Fremont 35
Genoa 35
Amsterdam 34
Charlotte 34
Zurich 34
Ninh Bình 33
Philadelphia 32
Quận Bình Thạnh 32
Thái Nguyên 32
Washington 31
Jinan 30
Bắc Ninh 29
Changsha 29
Mumbai 29
Totale 27.118
Salva come PNG Salva come JPEG
Nome #
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation 549
Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases 520
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 466
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 463
Diagnostic delay in bronchiectasis: an Italian perspective 452
Early referral to palliative care services in patients with IPF: A tool to take a step forward 401
Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study 389
Use of 6-minute walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases 383
What remains of long COVID after four years from hospitalization for severe COVID pneumonia 371
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 368
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 365
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 363
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 363
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 347
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 340
Clinical Characteristics of Anti-synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 329
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 322
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 305
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 304
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 304
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 299
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 297
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 296
Janus-faced amiodarone-induced pneumopathy 295
Interstiziopatia polmonare non classificabile o secondaria a connettivite indifferenziata. importanza e difficoltà di una diagnosi differenziale 290
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 286
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 286
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 280
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 280
A multidisciplinary approach to screen the post-COVID-19 conditions 274
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 268
The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis 266
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 261
Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review 255
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 255
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 254
Short-term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis 252
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 252
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 250
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 248
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 248
Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD 245
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 244
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 243
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 238
Pulmonary comorbidities associated with chronic obstructive pulmonary disease 236
Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis 234
Progression and prognosis of interstitial pneumonia with autoimmune features: a longitudinal, prospective, multi-centre study 233
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 232
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 231
Alteration of Lipid Metabolism in Patients with IPF and Its Association with Disease Severity and Prognosis: A Case–Control Study 227
Characteristics of long COVID after two years of follow-up in a previously hospitalized population 226
Evaluation of preoperative cardiopulmonary reserve and surgical risk of patients undergoing lung cancer resection 226
Sleep-Disordered Breathing and Chronic Respiratory Infections: A Narrative Review in Adult and Pediatric Population 222
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 222
Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach 220
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 219
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 219
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 218
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 217
Diagnosis of asthma and copd 214
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 212
Pulmonary Progressive Fibrosis in Rheumatoid Arthritis and Primary Sjogren Syndrome: Similarities and Differences 210
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 210
Idiopathic interstitial pneumonia in a patient with von Hippel-Lindau syndrome: a first case 208
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 208
Cystic lung in sarcoidosis: Clinico-radiologic characteristic and evolution 207
Clinical Impact of Vaping 207
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 205
Digital health technologies for improving the management of people with chronic obstructive pulmonary disease 204
Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: More questions than answers 204
The usual Interstitial pneumonia pattern in autoimmune rheumatic diseases 204
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 204
Questionnaires May Help Pulmonologists for Referral of Patients With IPF to a Holistic Approach 202
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 202
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 202
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 202
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 198
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 196
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 195
Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs 192
Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres 192
How do Climate Conditions and Urbanization Impact Non-Tuberculous Mycobacteria Infections? An Italian nationwide case-control study 192
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 187
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 187
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 185
Diagnostic Management of Pediatric Bronchiectasis: A Literature Review and Clinical Examples 185
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 184
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 183
Management of Idiopathic Pulmonary Fibrosis 182
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 182
Interstitial pneumonia associated with autoimmune diseases: a possible mimicker of SARS-CoV-2 pneumonia 182
The Multiple Components of COPD 181
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 179
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 179
Guiding ILD management in systemic autoimmune rheumatic diseases 175
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 175
Update in chronic obstructive pulmonary disease 2006 175
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 173
Clusterin (CLU) and lung cancer 173
Totale 25.485
Salva come PNG Salva come JPEG
Categoria #
all - tutte 155.835
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 155.835
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.691 0 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.467 55 66 93 76 330 607 547 85 281 33 35 259
2024/20257.621 400 1.168 430 326 609 308 546 218 687 1.115 586 1.228
2025/202620.559 2.499 1.593 1.480 2.077 1.812 1.010 2.647 1.029 1.685 1.508 1.618 1.601
2026/20272.412 1.088 1.324 0 0 0 0 0 0 0 0 0 0
Totale 44.835